viewAlder BioPharmaceuticals

Alder BioPharmaceuticals names Robert Azelby as new CEO

Azelby joins from Juno Therapeutics, where he worked as a chief commercial officer

woman with a migraine
Azelby helped oversee Juno’s acquisition by Celgene

Alder BioPharmaceuticals Inc (NASDAQ:ALDR), which specializes in treatments for migraines, has appointed a new chief who starts next week – Robert Azelby.

The Washington-based company’s new president and chief executive joins from Juno Therapeutics Inc, where he worked as an executive vice-president and chief commercial officer.

While at Juno, Azelby helped to oversee the company’s US$9bn acquisition by Celgene Corp (NASDAQ:CELG). He replaces Paul Cleveland who has been in the hot seat as Alder’s interim president and chief executive officer.

Azelby will serve on Alder’s board and Cleveland will also keep his seat as a director.

He's enthusiastic about the idea of bringing eptinezumab, Alder’s lead migraine drug, to market. “Eptinezumab has the potential to make a significant difference in the lives of people dealing with the debilitating effects of migraine,” Azelby said.

In early afternoon trade, Alder shares slumped 4.4% to US$17.35.

Quick facts: Alder BioPharmaceuticals

Price: - -

Market: NASDAQ
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Great Bear Resources sees more impressive results from their...

Great Bear Resources (CVE: GBR) President and CEO Chris Taylor joined Steve Darling from Proactive Vancouver with the latest results from their large drill program on the Dix Project in Red Lake, Ontario. Taylor telling Proactive they have expanded the shallow high-grade gold at the LP fault...

21 hours, 34 minutes ago

2 min read